Neumora Reports Favorable NMRA-215 Toxicology, Plans IND and Phase 1 Start in 2026

Neumora reported favorable pre-clinical toxicology for NMRA-215 and plans an IND submission in Q4 2026 with Phase 1 initiation by year-end.Key Highlights:Original SEC Filing: Neumora Therapeutics, Inc. [ NMRA ] - 8-K - Jul. 27, 2026This is an AI-powered summary. It may contain inaccuracies. Conside…

Neumora reported favorable pre-clinical toxicology for NMRA-215 and plans an IND submission in Q4 2026 with Phase 1 initiation by year-end.

Key Highlights:

Repeat 13-week rat study (162 animals) showed no unexpected in-life adverse findings, supporting safety of NMRA-215.
For-cause audit of prior rat study identified discrepancies; company believes prior adverse findings were not related to NMRA-215.
Neumora will submit an IND for NMRA-215 in Q4 2026 and aims to initiate a Phase 1 study by end of 2026.
NMRA-215 is a highly brain-penetrant oral NLRP3 inhibitor with preclinical efficacy in diet-induced obesity models and favorable cardiometabolic biomarkers.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.